Perioperative Outcomes After Radical Surgery Following EV Pembrolizumab in Urothelial Carcinoma - Daniel Roberson
Daniel Roberson discusses perioperative outcomes after enfortumab vedotin plus pembrolizumab, drawing on patients who underwent radical cystectomy or radical nephroureterectomy following this first-line combination.
ARASEC Design and Sensitivity Analyses of Darolutamide plus ADT in Metastatic Hormone-Sensitive Prostate Cancer - Rana McKay
Rana McKay
Rana McKay presents ARASEC, a phase 2 open-label study comparing darolutamide plus ADT against the ADT monotherapy arm from CHAARTED using propensity score matching.
